Open AccessPasireotide‐induced hyperglycemia in a patient with Cushing's disease: Potential use of sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist for treatment
Author(s) -
Shikata Masato,
Ashida Kenji,
Goto Yuka,
Nagayama Ayako,
Iwata Shimpei,
Yano Mamiko,
Hasuzawa Nao,
Hara Kento,
Mawatari Kazutoshi,
Sakata Kiyohiko,
Tsuruta Munehisa,
Wada Nobuhiko,
Nomura Masatoshi
Publication year - 2020
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.3230
Subject(s) - pasireotide , medicine , endocrinology , glucagon like peptide 1 , glucagon like peptide 1 receptor , type 2 diabetes , somatostatin , liraglutide , agonist , diabetes mellitus , acromegaly , receptor , growth hormone , hormone
Pasireotide improves hypercortisolemia and induces hyperglycemia via somatostatin receptor type‐5 stimulation. GLP‐1RA and SGLT2 inhibitor potentially help regulate hyperglycemia in patients with Cushing's disease, especially after pasireotide administration.